BioNTech Beheer

Beheer criteriumcontroles 4/4

De CEO BioNTech is Ugur Sahin, benoemd in Jan2008, heeft een ambtstermijn van 16.83 jaar. De totale jaarlijkse vergoeding van { bedraagt € 3.06M, bestaande uit 22.9% salaris en 77.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 17.23% van de aandelen van het bedrijf, ter waarde CHF 4.40B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 4.6 jaar.

Belangrijke informatie

Ugur Sahin

Algemeen directeur

€3.1m

Totale compensatie

Percentage CEO-salaris	22.9%
Dienstverband CEO	16.8yrs
Eigendom CEO	17.2%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	4.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ugur Sahin's beloning veranderd ten opzichte van BioNTech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-€467m
Jun 30 2024	n/a	n/a	-€504m
Mar 31 2024	n/a	n/a	€113m
Dec 31 2023	€3m	€700k	€930m
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€4b
Mar 31 2023	n/a	n/a	€6b
Dec 31 2022	€6m	€360k	€9b
Sep 30 2022	n/a	n/a	€10b
Jun 30 2022	n/a	n/a	€12b
Mar 31 2022	n/a	n/a	€13b
Dec 31 2021	€12m	€360k	€10b
Sep 30 2021	n/a	n/a	€7b
Jun 30 2021	n/a	n/a	€4b
Mar 31 2021	n/a	n/a	€1b
Dec 31 2020	€17m	€360k	€15m
Sep 30 2020	n/a	n/a	-€410m
Jun 30 2020	n/a	n/a	-€230m
Mar 31 2020	n/a	n/a	-€192m
Dec 31 2019	€7m	€311k	-€179m
Sep 30 2019	n/a	n/a	-€122m
Jun 30 2019	n/a	n/a	-€116m
Mar 31 2019	n/a	n/a	-€77m
Dec 31 2018	€653k	€210k	-€48m

Compensatie versus markt: De totale vergoeding ($USD 3.23M ) Ugur } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 4.76M ).

Compensatie versus inkomsten: De vergoeding van Ugur is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ugur Sahin (59 yo)

16.8yrs

Tenure

€3,056,000

Compensatie

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ugur Sahin	Co-Founder	16.8yrs	€3.06m	17.23% CHF 4.4b
Ozlem Tureci	Co-Founder	6.8yrs	€814.00k	0.38% CHF 97.4m
Jens Holstein	CFO & Member of Management Board	3.3yrs	€1.32m	0.00068% CHF 173.8k
Sierk Poetting	MD, COO & Member of Management Board	10.8yrs	€821.00k	0.31% CHF 80.5m
Ryan Richardson	Chief Strategy Officer	4.8yrs	€1.41m	0.0061% CHF 1.6m
James Timothy Ryan	Chief Legal & Business Officer & Member of the Management Board	1.2yrs	€848.00k	geen gegevens
Sean Marett	Executive Officer	less than a year	€133.00k	0.34% CHF 86.9m
Lisa Birringer	Senior Vice President of Global Financial Reporting & Accounting	less than a year	geen gegevens	geen gegevens
Zach Taylor	Senior Vice President of Corporate Development & Strategy	less than a year	geen gegevens	geen gegevens
Katalin Kariko	Senior VP & External Consultant for RNA Protein Replacement Therapies	no data	geen gegevens	geen gegevens
Oliver Henning	Senior Vice President of Operations	no data	geen gegevens	geen gegevens
Sebastian Kreiter	Senior Vice President of Immunotherapy & Preclinical Research	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 22UA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rudolf Staudigl	Supervisory Board Member	2.4yrs	€90.00k	0.00017% CHF 43.4k
Ulrich Wandschneider	Independent Deputy Chairman Supervisory Board	6.8yrs	€114.00k	geen gegevens
Michael Motschmann	Independent Supervisory Board Member	16.8yrs	€80.00k	geen gegevens
Helmut Jeggle	Independent Supervisory Board Chairman	16.8yrs	€226.00k	0.14% CHF 35.4m
Nicola Blackwood	Member of Supervisory Board	1.5yrs	€46.00k	geen gegevens
Anja Morawietz	Supervisory Board Member	2.4yrs	€105.00k	0.00010% CHF 25.6k

4.6yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 22UA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

BioNTech Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023)

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

New major risk - Revenue and earnings growth

New major risk - Share price stability

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: €1.31 loss per share (vs €2.07 profit in 1Q 2023)

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

Full year 2023 earnings released: EPS: €3.87 (vs €38.78 in FY 2022)

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

New minor risk - Shareholder dilution

Now 21% overvalued

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd